Avenzo Therapeutics Presents Initial Results from the Phase 1/2 Study of AVZO-021, a Potential Best-in-Class CDK2 Inhibitor, at the 2025 San Antonio Breast Cancer Symposium Avenzo Therapeutics, Inc. ( ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback